TEQUIN SUMMARY
TEQUIN contains gatifloxacin, a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration.
TEQUIN (gatifloxacin) is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below (see DOSAGE AND ADMINISTRATION).
Acute bacterial exacerbation of chronic bronchitis due to
Streptococcus pneumoniae,
Haemophilus influenzae,
Haemophilus parainfluenzae,
Moraxella catarrhalis, or
Staphylococcus aureus.
Acute sinusitis due to
Streptococcus pneumoniae
or
Haemophilus influenzae.
Community-acquired pneumonia due to
Streptococcus pneumoniae,
Haemophilus influenzae,
Haemophilus parainfluenzae,
Moraxella catarrhalis,
Staphylococcus aureus,
Mycoplasma pneumoniae,
Chlamydia pneumoniae, or
Legionella pneumophila.
Uncomplicated skin and skin structure infections (i.e., simple abscesses, furuncles, folliculitis, wound infections, and cellulitis) due to
Staphylococcus aureus
(methicillin-susceptible strains only) or
Streptococcus pyogenes.
NOTE: An insufficient number of patients with the diagnosis of impetiginous lesions were available for evaluation.
Uncomplicated urinary tract infections (cystitis) due to
Escherichia coli,
Klebsiella pneumoniae, or
Proteus mirabilis.
Complicated urinary tract infections due to
Escherichia coli,
Klebsiella pneumoniae, or
Proteus mirabilis.
Pyelonephritis due to
Escherichia coli.
Uncomplicated urethral and cervical gonorrhea due to
Neisseria gonorrhoeae. Acute, uncomplicated rectal infections in women due to
Neisseria gonorrhoeae
(see WARNINGS).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEQUIN and other antibacterial drugs, TEQUIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
